This site is intended for healthcare professionals

New phase III data support the sustained, long-acting efficacy of lenacapavir

Read time: 3 mins
Last updated:28th Jul 2021
Published:19th Jul 2021
Gilead Sciences, Inc. announced new results from the ongoing Phase II/III CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV.
Condition: HIV/AIDS
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest